Auron Therapeutics is developing next-generation targeted cancer therapies by identifying and targeting the drivers of the disrupted cell states found in cancer, and reverting cancer cells from a plastic, proliferative cell state to a more mature, non-proliferative cell state. Using its AURIGIN™ platform, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, for the treatment of both solid tumors and hematologic malignancies.
Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model